Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H21ClN2O8 |
Molecular Weight | 476.864 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12[C@@H](O)[C@]3([H])C(=C)C4=C(Cl)C=CC(O)=C4C(=O)C3=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C
InChI
InChIKey=GGQJXCQBBONZFX-IWVLMIASSA-N
InChI=1S/C22H21ClN2O8/c1-6-9-7(23)4-5-8(26)11(9)16(27)12-10(6)17(28)14-15(25(2)3)18(29)13(21(24)32)20(31)22(14,33)19(12)30/h4-5,10,14-15,17,26,28-30,33H,1H2,2-3H3,(H2,24,32)/t10-,14-,15+,17+,22+/m1/s1
Molecular Formula | C22H21ClN2O8 |
Molecular Weight | 476.864 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Meclocycline is a tetracycline antibiotic. It is used topically for skin infections treatment. Tetracyclines are broad-spectrum bacteriostatic agents and act by inhibiting protein synthesis by blocking the binding of aminoacyl tRNA (transfer RNA) to the mRNA (messenger RNA) ribosome complex. Meclocycline might increase sensitivity to light when it is used with Aminolevulinic acid.
Originator
Approval Year
Doses
Dose | Population | Adverse events |
---|---|---|
1 % 2 times / day multiple, topical Recommended Dose: 1 %, 2 times / day Route: topical Route: multiple Dose: 1 %, 2 times / day Sources: Page: p.177 |
unhealthy, 12-37 n = 33 Health Status: unhealthy Condition: Acne vulgaris Age Group: 12-37 Sex: M+F Population Size: 33 Sources: Page: p.177 |
Other AEs: Yellow skin... |
1 % 2 times / day multiple, topical Recommended Dose: 1 %, 2 times / day Route: topical Route: multiple Dose: 1 %, 2 times / day Sources: |
unhealthy |
Other AEs: Contact dermatitis... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Yellow skin | 6% | 1 % 2 times / day multiple, topical Recommended Dose: 1 %, 2 times / day Route: topical Route: multiple Dose: 1 %, 2 times / day Sources: Page: p.177 |
unhealthy, 12-37 n = 33 Health Status: unhealthy Condition: Acne vulgaris Age Group: 12-37 Sex: M+F Population Size: 33 Sources: Page: p.177 |
Contact dermatitis | 1 % 2 times / day multiple, topical Recommended Dose: 1 %, 2 times / day Route: topical Route: multiple Dose: 1 %, 2 times / day Sources: |
unhealthy |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Noticeable improvement may be seen in 4 to 6 weeks. In some patients it may require up to 6 to 8 weeks of treatment before noticeable improvement is seen and up to 8 to 12 weeks before maximum benefit is seen.
Two times a day, morning and evening.
Route of Administration:
Topical
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:10:30 GMT 2023
by
admin
on
Sat Dec 16 17:10:30 GMT 2023
|
Record UNII |
23Q8M2HE6S
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1595
Created by
admin on Sat Dec 16 17:10:30 GMT 2023 , Edited by admin on Sat Dec 16 17:10:30 GMT 2023
|
||
|
WHO-ATC |
D10AF04
Created by
admin on Sat Dec 16 17:10:30 GMT 2023 , Edited by admin on Sat Dec 16 17:10:30 GMT 2023
|
||
|
WHO-VATC |
QD10AF04
Created by
admin on Sat Dec 16 17:10:30 GMT 2023 , Edited by admin on Sat Dec 16 17:10:30 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
29418
Created by
admin on Sat Dec 16 17:10:30 GMT 2023 , Edited by admin on Sat Dec 16 17:10:30 GMT 2023
|
PRIMARY | RxNorm | ||
|
3333
Created by
admin on Sat Dec 16 17:10:30 GMT 2023 , Edited by admin on Sat Dec 16 17:10:30 GMT 2023
|
PRIMARY | |||
|
C100122
Created by
admin on Sat Dec 16 17:10:30 GMT 2023 , Edited by admin on Sat Dec 16 17:10:30 GMT 2023
|
PRIMARY | |||
|
1566
Created by
admin on Sat Dec 16 17:10:30 GMT 2023 , Edited by admin on Sat Dec 16 17:10:30 GMT 2023
|
PRIMARY | |||
|
SUB08677MIG
Created by
admin on Sat Dec 16 17:10:30 GMT 2023 , Edited by admin on Sat Dec 16 17:10:30 GMT 2023
|
PRIMARY | |||
|
MECLOCYCLINE
Created by
admin on Sat Dec 16 17:10:30 GMT 2023 , Edited by admin on Sat Dec 16 17:10:30 GMT 2023
|
PRIMARY | |||
|
23Q8M2HE6S
Created by
admin on Sat Dec 16 17:10:30 GMT 2023 , Edited by admin on Sat Dec 16 17:10:30 GMT 2023
|
PRIMARY | |||
|
DTXSID4048567
Created by
admin on Sat Dec 16 17:10:30 GMT 2023 , Edited by admin on Sat Dec 16 17:10:30 GMT 2023
|
PRIMARY | |||
|
100000081776
Created by
admin on Sat Dec 16 17:10:30 GMT 2023 , Edited by admin on Sat Dec 16 17:10:30 GMT 2023
|
PRIMARY | |||
|
217-938-3
Created by
admin on Sat Dec 16 17:10:30 GMT 2023 , Edited by admin on Sat Dec 16 17:10:30 GMT 2023
|
PRIMARY | |||
|
C61825
Created by
admin on Sat Dec 16 17:10:30 GMT 2023 , Edited by admin on Sat Dec 16 17:10:30 GMT 2023
|
PRIMARY | |||
|
CHEMBL1237124
Created by
admin on Sat Dec 16 17:10:30 GMT 2023 , Edited by admin on Sat Dec 16 17:10:30 GMT 2023
|
PRIMARY | |||
|
m7119
Created by
admin on Sat Dec 16 17:10:30 GMT 2023 , Edited by admin on Sat Dec 16 17:10:30 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB13092
Created by
admin on Sat Dec 16 17:10:30 GMT 2023 , Edited by admin on Sat Dec 16 17:10:30 GMT 2023
|
PRIMARY | |||
|
2013-58-3
Created by
admin on Sat Dec 16 17:10:30 GMT 2023 , Edited by admin on Sat Dec 16 17:10:30 GMT 2023
|
PRIMARY | |||
|
78502
Created by
admin on Sat Dec 16 17:10:30 GMT 2023 , Edited by admin on Sat Dec 16 17:10:30 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |